William Blair analyst Sami Corwin has maintained their bullish stance on PTCT stock, giving a Buy rating on February 18.
Sami Corwin has given his Buy rating due to a combination of factors including PTC Therapeutics’ strong financial performance and strategic partnerships. The company reported a solid revenue increase in the fourth quarter, with a total of $213.2 million, marking an 8% growth compared to the previous quarter. Although the full-year revenue for 2024 slightly missed initial estimates, the company’s robust cash position, bolstered by a $1 billion collaboration with Novartis, enhances its financial stability and supports future commercial launches.
Additionally, PTC Therapeutics is poised for growth with its upcoming global launch of Sepiapterin in PKU, expected to gain CHMP opinion in the second quarter of 2025. The company’s strategic focus on its DMD franchise and the anticipated revenue from its collaboration with Roche further strengthen its market position. These elements collectively contribute to the positive outlook and justify the Buy rating assigned by Sami Corwin.
In another report released on February 18, RBC Capital also reiterated a Buy rating on the stock with a $63.00 price target.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.